Literature DB >> 16682661

Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy.

P C Souverein1, D J Webb, J G Weil, T P Van Staa, A C G Egberts.   

Abstract

OBJECTIVE: To study the association between use of antiepileptic drugs (AEDs) and risk of fractures.
METHODS: The authors obtained data from the General Practice Research Database (GPRD). A case-control study was nested within a cohort of patients with active epilepsy. Cases were patients with a first fracture after cohort entry. Up to four controls were matched to each case by practice, sex, year of birth, timing of first epilepsy diagnosis, index date, and duration of GPRD history. Cumulative exposure to AEDs was assessed by summing the duration of all AED prescriptions. A distinction was made between AEDs that induce the hepatic cytochrome P-450 enzyme system and AEDs that do not. Medical conditions and drugs known to be associated with bone metabolism or falls were evaluated as potential confounders. Conditional logistic regression analysis was used to calculate odds ratios (ORs) and 95% CIs.
RESULTS: The study population comprised 1,018 cases and 1,842 matched controls. The risk of fractures increased with cumulative duration of exposure (p for trend < 0.001), with the strongest association for greater than 12 years of use: adjusted OR 4.15 (95% CI 2.71 to 6.34). Risk estimates were higher in women than in men. There was no difference between users of AEDs that induce and AEDs that do not induce the hepatic cytochrome P-450 system.
CONCLUSIONS: Long-term use of AEDs was associated with an increased risk of fractures, especially in women. More research on mechanisms of AED-induced bone breakdown and female vulnerability to the effects of AEDs on bone health is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682661     DOI: 10.1212/01.wnl.0000210503.89488.88

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  47 in total

1.  The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Authors:  Erik K St Louis
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

2.  Prevalence and risk factors for vitamin D insufficiency among children with epilepsy.

Authors:  Renée A Shellhaas; Amanda K Barks; Sucheta M Joshi
Journal:  Pediatr Neurol       Date:  2010-06       Impact factor: 3.372

3.  Low vitamin D levels are common in patients with epilepsy.

Authors:  Diane L Teagarden; Kimford J Meador; David W Loring
Journal:  Epilepsy Res       Date:  2014-07-06       Impact factor: 3.045

Review 4.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

Review 5.  Drug-Nutrition Interactions and the Brain: It's Not All in Your Head.

Authors:  Joseph I Boullata
Journal:  Curr Nutr Rep       Date:  2019-06

6.  Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs.

Authors:  Alison M Pack; Martha J Morrell; Don J McMahon; Elizabeth Shane
Journal:  Epilepsy Behav       Date:  2011-06-25       Impact factor: 2.937

7.  Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk.

Authors:  B Abrahamsen; K Brixen
Journal:  Osteoporos Int       Date:  2008-08-09       Impact factor: 4.507

Review 8.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

9.  Antiepileptic drug use and rates of hip bone loss in older men: a prospective study.

Authors:  K E Ensrud; T S Walczak; T L Blackwell; E R Ensrud; E Barrett-Connor; E S Orwoll
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

10.  Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care.

Authors:  Erik K St Louis; Erik K Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.